Lophos Pharmaceuticals Corp. CEO Claire Stawnyczy Presenting at O’Cannabiz Psychedelics Summit – June 2nd
Napanee, Ontario–(Newsfile Corp. – May 31, 2022) – Lophos Pharmaceuticals Corp., a Canadian biosciences research and development company that focuses on Peyote cultivation and Peyote derived compounds will be participating in the upcoming O’Cannabiz Psychedelic summit June 2nd at the International Centre Hall #5 in Mississauga, Ontario. CEO and President Claire Stawnyczy is proud to share her vision with conference attendees, in how she intends to build a sustainable pathway for medical research on traditional/indigenous medical plants.
Claire Stawnyczy, CEO will be speaking at 2:50-3:45 PM ET on June 2nd. Interested parties can register here. Claire will be presenting on the panel titled – “Seeking The Magic Mushroom: Mystical Experiences and Tradition in a Medical Paradigm” moderated by Amanda Siebert, alongside fellow panelists Dr. Ivan Casselman, Chief Psychedelic Officer at HAVN; and Dr. Jacob Vogan, CSO & Co-Founder of CB Therapeutics (CBT). Together the panel will provide insights on the renowned psychedelics article ‘Seeking the Magic Mushroom’ and how it has changed the west’s orientation to psychedelic medicine. Panelists will discuss the importance of this heritage, how and where it should be maintained, the acknowledgement and recognition of indigenous practices, and the translation of these practices into modern therapies.
CEO Backgrounder: Claire Stawnyczy
Claire is the CEO of Lophos Pharmaceuticals Corp., a psychedelic biosciences company focused on exploring Peyote derivatives, and has a strong scientific and regulatory background. She studied Cell & Molecular Biology and Industrial Biotechnology, then gained substantial experience working in large-scale cell culture fermentation, protein purification, and pharmaceutical manufacturing. Claire is also a co-founder of Canalytica Corp., a cannabis industry business management and regulatory consulting firm. From her experience working in the cannabis industry, Claire has supported over 20 licensed producers, led cannabis process validation for EU-GMP approval, Health Canada licensing from initial application submissions to audit response, and regulated product development.
About Lophos Pharmaceuticals Corp.
Lophos is a biosciences company that specializes in Peyote research, cultivation, preservation, and drug development. We develop novel therapies and natural health treatments that aim to restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques, Lophos Pharmaceuticals will provide our partners with medical grade inputs and our patients with access to safe and effective mescaline-based therapeutics.
About O’Cannabiz Conference
The producers of O’ Cannabiz Conference Expo & Awards have decades of experience producing national high-profile events, and creating global connections between business communities in the arts, broadcasting, media and technology industries. They have organized trade summit initiatives with governments around the globe, and they have worked closely with sponsors in all levels of Canadian government.
Their signature events include the internationally-attended Canadian Music Week, Digital Media Summit, Radio Interactive Summit, and the career-breaking CMW Music Festival.
They produce a myriad of entertainment and media industry awards, including: The Indies, The Canadian Radio Music Awards, the advertising industry’s Crystal Awards, The Live Music Industry Awards, and the annual Music Broadcast and Industry Gala. They also maintain a healthy two-decades-long relationship with Canada’s Juno Awards.
Veterans at assembling groups of innovators, thought leaders and industry professionals, the O’Cannabiz Team is now applying their expertise at creating new business roadmaps for the future, and bringing forth thoughtful discussions through panels and webinars featuring hot-button issues of the day.
For further information:
Alex Krause
519-835-8345
alexkrause.pr@gmail.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125914
